Journal
MEDCHEMCOMM
Volume 6, Issue 5, Pages 947-955Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c5md00027k
Keywords
-
Ask authors/readers for more resources
A novel series of potent, selective, and orally efficacious dual antagonists of the orexin receptors has been investigated, resulting in the identification of lead compound 27 (HTL6641). Comprehensive data for 27 are presented, including in vivo PK parameters, confirmation of receptor occupancy through ex vivo binding and efficacy in a rat sleep model. A key feature of the series is a short dissociation half-life, measured by surface plasmon resonance (SPR) using stabilized receptors, and confirmed by radioligand-binding experiments. Based on a consideration of the requirements for a potential treatment for insomnia, compound 27 was identified as having the best balance of properties from the chemical series.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available